FATE FATE THERAPEUTICS INC

BEARISH Impact: 5/10 Institutional Cluster
Horizon weeks Processed 3d 13h ago
Institutional cluster: 2 buyers, 5 sellers (bearish)

Executive Summary

FATE Therapeutics saw a bearish institutional cluster in Q3 2025, with 5 sellers (including Citadel near-exiting a $5.1M position) overwhelming 2 quant buyers (RenTech and Two Sigma doubling small positions). Net selling of ~$6M signals fading conviction among major holders, consistent with the stock's small $218M market cap and ongoing sector headwinds.

Key Financial Metrics

Direction
distributing
Buy Value
$2.7M
Sell Value
$6.0M
Net Flow
-$3.3M

Institutional Positions

Net institutional flow: -$3.3M

▲ Buyers (2)

InstitutionActionChangePosition ValueValue Δ
RenTech DOUBLED +488.7% $1.6M $1.4M
Two Sigma DOUBLED +294.4% $1.1M $879.0K

▼ Sellers (5)

InstitutionActionChangePrev ValueValue Δ
Citadel NEAR_EXIT -81.9% $5.1M -$4.1M
Morgan Stanley TRIM -61.8% $2.7M -$1.6M
UBS TRIM -67.3% $1.1M -$681.6K
Barclays TRIM -53.5% $507.00 $265.0K
Fidelity TRIM -69.2% $38.0K -$24.9K

Actionable Insight

The cluster suggests institutional de-risking ahead of potential catalysts or continued cash burn. Monitor for further insider selling or a capital raise, as the selling pressure from large holders like Citadel and Morgan Stanley may persist. The quant buying is small and likely algorithmic, not thesis-driven.

Key Facts

  • 5 institutional sellers vs 2 buyers in Q3 2025
  • Citadel reduced 81.9% of its position, selling ~$4.1M worth
  • RenTech and Two Sigma doubled small positions but combined buying was only $2.2M
  • Net institutional outflow of ~$6M, dominated by passive/quant trimming
  • FATE market cap is $218M; the cluster represents ~2.8% of float

Financial Impact

Net institutional selling of approximately $6.0M, with Citadel alone accounting for $4.1M of that. Buyers added $2.2M, but sellers reduced $6.0M.

institutional ownershipfloat turnover

Risk Factors

  • Further institutional selling could pressure the stock given the small float
  • Cash burn and lack of near-term revenue catalysts may drive additional exits
  • Quant buying is low-conviction and may reverse quickly

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
61% bullish (18 analysts)

Documents Analyzed

This report is based on 1 institutional 13F filing from SEC EDGAR.

DocumentAccession Number
INST-CLUSTER Data (Synthetic)inst-cluster-FATE-2025-Q3
6 reports for FATE
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for FATE — sortable, filterable
Type Now
Jun 11, 2026
3d ago
Institutional Cluster
BEARISH ★ 5/10
$1.95 awaiting T+5awaiting T+5
Jun 4, 2026
10d ago
8-K
NEUTRAL ★ 4/10
$2.15 awaiting T+5awaiting T+5
Jun 1, 2026
13d ago
Press Release
BULLISH ★ 6/10
$2.74 $1.98▼ −27.74%▼ −24.99%
May 13, 2026
4w ago
8-K
NEUTRAL ★ 5/10
$2.14 $1.89▼ −11.68%▼ −10.52%
May 11, 2026
4w ago
Press Release
BULLISH ★ 7/10
$2.18 $1.73▼ −20.64%▼ −20.56%
Apr 24, 2026
7w ago
DEFA14A
NEUTRAL ★ 3/10
$1.31 $1.80▲ +37.40%▲ +37.00%
Showing 6 of 6

US Market Status

Market Closed — Opens in 4h 30m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access